Risk Factors and Predictive Models for Intravenous Immunoglobulin Resistance in Children with Recurrent Kawasaki Disease

References

• Burns JC, Glodé MP. Kawasaki syndrome. Lancet. 2004;364(9433):533–544. doi:10.1016/S0140-6736(04)16814-1
   PubMed Web of Science ®Google Scholar
• Matsubara T, Ichiyama T, Furukawa S. Immunological profile of peripheral blood lymphocytes and monocytes/macrophages in Kawasaki disease. Clin Exp Immunol. 2005;141(3):381–387. doi:10.1111/j.1365-2249.2005.02821.x
   PubMed Web of Science ®Google Scholar
• Singh S, Vignesh P, Burgner D. The epidemiology of Kawasaki disease: a global update. Arch Dis Child. 2015;100(11):1084–1088. doi:10.1136/archdischild-2014-307536
   PubMed Web of Science ®Google Scholar
• Chang LY, Lu CY, Shao PL, et al. Viral infections associated with Kawasaki disease. J Formos Med Assoc. 2014;113(3):148–154. doi:10.1016/j.jfma.2013.12.008
   PubMed Web of Science ®Google Scholar
• Sudo D, Nakamura Y. Nationwide surveys show that the incidence of recurrent Kawasaki disease in Japan has hardly changed over the last 30 years. Acta Paediatr. 2017;106(5):796–800. doi:10.1111/apa.13773
   PubMed Web of Science ®Google Scholar
• Sudo D, Makino N, Nakamura Y. Recurrent Kawasaki disease and cardiac complications: nationwide surveys in Japan. Arch Dis Child. 2020;105(9):848–852. doi:10.1136/archdischild-2019-317238
   PubMed Web of Science ®Google Scholar
• Kim GB, Han JW, Park YW, et al. Epidemiologic features of Kawasaki disease in South Korea: data from nationwide survey, 2009–2011. Pediatr Infect Dis J. 2014;33(1):24–27. doi:10.1097/INF.0000000000000010
   PubMed Web of Science ®Google Scholar
• Maddox RA, Holman RC, Uehara R, et al. Recurrent Kawasaki disease: USA and Japan. Pediatr Int. 2015;57(6):1116–1120. doi:10.1111/ped.12733
   PubMed Web of Science ®Google Scholar
• Chahal N, Somji Z, Manlhiot C, et al. Rate, associated factors and outcomes of recurrence of Kawasaki disease in Ontario, Canada. Pediatr Int. 2012;54(3):383–387. doi:10.1111/j.1442-200X.2012.03628.x
   PubMed Web of Science ®Google Scholar
• Rowley AH. Multisystem Inflammatory syndrome in children and Kawasaki disease: two different illnesses with overlapping clinical features. J Pediatr. 2020;224:129–132. doi:10.1016/j.jpeds.2020.06.057
   PubMed Web of Science ®Google Scholar
• McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017;135(17):e927–e999. doi:10.1161/CIR.0000000000000484
   PubMed Web of Science ®Google Scholar
• Zheng X, Li J, Yue P, et al. Is there an association between intravenous immunoglobulin resistance and coronary artery lesion in Kawasaki disease? Current evidence based on a meta-analysis. PLoS One. 2021;16(3):e0248812. doi:10.1371/journal.pone.0248812
   PubMed Web of Science ®Google Scholar
• Zhu F, Ang JY. 2021 update on the clinical management and diagnosis of Kawasaki disease. Curr Infect Dis Rep. 2021;23(3):3. doi:10.1007/s11908-021-00746-1
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation. 2006;113(22):2606–2612. doi:10.1161/CIRCULATIONAHA.105.592865
   PubMed Web of Science ®Google Scholar
• Egami K, Muta H, Ishii M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr. 2006;149(2):237–240. doi:10.1016/j.jpeds.2006.03.050
   PubMed Web of Science ®Google Scholar
• Sano T, Kurotobi S, Matsuzaki K, et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr. 2007;166(2):131–137. doi:10.1007/s00431-006-0223-z
   PubMed Web of Science ®Google Scholar
• Tang Y, Yan W, Sun L, et al. Prediction of intravenous immunoglobulin resistance in Kawasaki disease in an East China population. Clin Rheumatol. 2016;35(11):2771–2776. doi:10.1007/s10067-016-3370-2
   PubMed Web of Science ®Google Scholar
• Yang S, Song R, Zhang J, Li X, Li C. Predictive tool for intravenous immunoglobulin resistance of Kawasaki disease in Beijing. Arch Dis Child. 2019;104(3):262–267. doi:10.1136/archdischild-2017-314512
   PubMed Web of Science ®Google Scholar
• Tan XH, Zhang XW, Wang XY, et al. A new model for predicting intravenous immunoglobin-resistant Kawasaki disease in Chongqing: a retrospective study on 5277 patients. Sci Rep. 2019;9(1):1722. doi:10.1038/s41598-019-39330-y
   PubMed Web of Science ®Google Scholar
• Okada K, Hara J, Maki I, et al. Pulse methylprednisolone with gammaglobulin as an initial treatment for acute Kawasaki disease. Eur J Pediatr. 2009;168(2):181–185. doi:10.1007/s00431-008-0727-9
   PubMed Web of Science ®Google Scholar
• Ogata S, Ogihara Y, Honda T, Kon S, Akiyama K, Ishii M. Corticosteroid pulse combination therapy for refractory Kawasaki disease: a randomized trial. Pediatrics. 2012;129(1):e17–e23. doi:10.1542/peds.2011-0148
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Saji T, Otani T, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet. 2012;379(9826):1613–1620. doi:10.1016/S0140-6736(11)61930-2
   PubMed Web of Science ®Google Scholar
• Diagnosis SP. Pediatric expert consensus on the application of glucocorticoids in Kawasaki disease. Zhongguo Dang Dai Er Ke Za Zhi. 2022;24(3):225–231. doi:10.7499/j.issn.1008-8830.2112033
   PubMedGoogle Scholar
• Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the committee on rheumatic fever, endocarditis and Kawasaki disease, council on cardiovascular disease in the Young, American Heart Association. Circulation. 2004;110(17):2747–2771. doi:10.1161/01.CIR.0000145143.19711.78
   PubMed Web of Science ®Google Scholar
• Hirata S, Nakamura Y, Yanagawa H. Incidence rate of recurrent Kawasaki disease and related risk factors: from the results of nationwide surveys of Kawasaki disease in Japan. Acta Paediatr. 2001;90(1):40–44. doi:10.1111/j.1651-2227.2001.tb00253.x
   PubMed Web of Science ®Google Scholar
• Tibshirani R. Regression Shrinkage and Selection Via the Lasso. J R Stat Soc. 1996;58(1):267–288.
   Google Scholar
• Moons KGM, Altman DG, Reitsma JB, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med. 2015;162(1):W1–W73. doi:10.7326/M14-0698
   PubMed Web of Science ®Google Scholar
• Yuan M, Lin Y. Model selection and estimation in regression with grouped variables. J R Stat Soc. 2006;68(1):49–67. doi:10.1111/j.1467-9868.2005.00532.x
   Google Scholar
• Mandrekar JN. Receiver operating characteristic curve in diagnostic test assessment. J Thorac Oncol. 2010;5(9):1315–1316. doi:10.1097/JTO.0b013e3181ec173d
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Yashiro M, Uehara R, et al. Epidemiologic features of Kawasaki disease in Japan: results of the 2009–2010 nationwide survey. J Epidemiol. 2012;22(3):216–221. doi:10.2188/jea.JE20110126
   PubMed Web of Science ®Google Scholar
• Ae R, Makino N, Kosami K, Kuwabara M, Matsubara Y, Nakamura Y. Epidemiology, Treatments, and Cardiac Complications in Patients with Kawasaki Disease: the nationwide survey in Japan, 2017–2018. J Pediatr. 2020;225:23–29.e22. doi:10.1016/j.jpeds.2020.05.034
   PubMed Web of Science ®Google Scholar
• Luo G, Pan S-L, Wang S-B, Du Z-H, Ji Z-X. Clinical features of children with recurrent Kawasaki disease: a Meta analysis. Zhongguo dang dai er ke za zhi. 2020;22(12):1306–1312.
   PubMedGoogle Scholar
• Yang HM, Du ZD, Fu PP. Clinical features of recurrent Kawasaki disease and its risk factors. Eur J Pediatr. 2013;172(12):1641–1647. doi:10.1007/s00431-013-2101-9
   PubMed Web of Science ®Google Scholar
• Huang WC, Huang LM, Chang IS, et al. Epidemiologic features of Kawasaki disease in Taiwan, 2003–2006. Pediatrics. 2009;123(3):e401–e405. doi:10.1542/peds.2008-2187
   PubMed Web of Science ®Google Scholar
• Xie LP, Yan WL, Huang M, et al. Epidemiologic Features of Kawasaki Disease in Shanghai from 2013 through 2017. J Epidemiol. 2020;30(10):429–435. doi:10.2188/jea.JE20190065
   PubMed Web of Science ®Google Scholar
• Bar-Meir M, Kalisky I, Schwartz A, Somekh E, Tasher D. Prediction of resistance to intravenous immunoglobulin in children with Kawasaki disease. J Pediatric Infect Dis Soc. 2018;7(1):25–29. doi:10.1093/jpids/piw075
   PubMed Web of Science ®Google Scholar
• Kido S, Ae R, Kosami K, et al. Seasonality of i.v. immunoglobulin responsiveness in Kawasaki disease. Pediatr Int. 2019;61(6):539–543. doi:10.1111/ped.13863
   PubMed Web of Science ®Google Scholar
• Kang SJ, Jin BK, Hwang SJ, Kim HJ. Sequential changes in left ventricular systolic myocardial deformation mechanics in children with recurrent Kawasaki disease. J Cardiovasc Imaging. 2018;26(3):147–154. doi:10.4250/jcvi.2018.26.e12
   PubMedGoogle Scholar
• Liu G, Wang S, Du Z. Risk factors of intravenous immunoglobulin resistance in children with Kawasaki disease: a meta-analysis of Case-Control Studies. Front Pediatr. 2020;8:187. doi:10.3389/fped.2020.00187
   PubMed Web of Science ®Google Scholar
• Lin MT, Chang CH, Sun LC, et al. Risk factors and derived formosa score for intravenous immunoglobulin unresponsiveness in Taiwanese children with Kawasaki disease. J Formos Med Assoc. 2016;115(5):350–355. doi:10.1016/j.jfma.2015.03.012
   PubMed Web of Science ®Google Scholar